Roth MKM raised the firm’s price target on Orthofix to $15 from $12 and keeps a Neutral rating on the shares. The firm is citing the company’s better than expected Q4 revenue, which marks a “solid performance” in light of management disruptions, the analyst tells investors in a research note. Orthofix’s 2024 guidance also appears conservative, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OFIX:
- New Debt & Financing Risk for Orthofix International – What’s the Latest?
- Orthofix sees FY24 revenue $785M-$795M, consensus $798.6M
- Orthofix reports Q4 adjusted EBITDA $19.6M vs. $10.0M last year
- Orthofix International’s Strategy for Investor Engagement
- Orthofix reports Q4 adjusted EBITDA $46.3M vs. $48.6M last year